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Abstract
Leukemic blasts from patients with acute myeloid leukemia (AML) frequently express high levels of the interleukin-3 receptor α chain (IL-3Rα).
In the present study, we have explored the sensitivity of primary leukemic blasts obtained from 34 AML patients to a diphtheria toxin (DT) composed of the catalytic and translocation domains of DT (DT 388 Flt3 is mutated and/or overexpressed in 30-40% of AMLs (3), while the IL-3R is overexpressed in about 45% of AMLs (4) . Furthermore, the analysis of an AML subpopulation enriched in leukemic stem cells showed that these cells express elevated levels of IL-3Rα, while in the normal counterpart low levels of IL-3Rα have been observed, thus indicating that the IL-3Rα is a unique marker of leukemic stem cells (5) . According to these findings it has been suggested that the IL-3R may represent an important target for the development of new antileukemic drugs (6) .
A genetically engineered fusion toxin composed of the first 388 amino acid residues of diphtheria toxin (DT) with an H-M linker fused to human IL-3 (7). This IL-3 DT was found to be toxic towards leukemic blasts (8) and in vivo studies in Cynomolgus monkeys have shown that it is relatively well tolerated up to 100 µg/Kg (9, 10) . These results contrast with the limited tolerance to the GMCSF DT fusion protein (DT 388 GMCSF) which produced liver injury above 4 -7 µg/kg in monkeys and AML patients (11, 12).
Preclinical studies with rodent cell directed DT fusion proteins 
MATERIALS AND METHODS

Cells
Fresh leukemic blasts from 34 AML patients, obtained after informed consent, were isolated from either bone marrow or peripheral blood by Approval for these studies was obtained from the institutional review board.
Informed consent was obtained according to the Declaration of Helsinki.
Preparation of DT 388 IL-3
The preparation and purification of DT 388 IL-3 and DT 388 IL-3[K116W] has been previously reported in detail (7, 8) . for the presence of apoptotic cells using the Annexin V binding assay.
RESULTS AND DISCUSSION
Newly diagnosed AML patients were investigated for their in vitro sensitivity to the DT fused to the wild-type IL-3 (DT 388 IL-3) and to the DT fused to We therefore tested the effects of the two fusion proteins at 1x10 (Fig. 1 B) .
It is of interest to note that the rate of cell killing induced by these diphtheria IL-3 fusion proteins varied among the different AML cases tested. In order to understand the origin of this heterogeneity we investigated whether the rate of blast cell killing induced by the IL-3 diphtheria fusion proteins was dependent upon the levels of IL-3R expression on leukemic cells. For this purpose, the expression of IL-3Rα (CD123) and IL-3Rβ (CDw131) was analyzed by flow cytometry using specific monoclonal antibodies conjugated with phycoerythrin. This analysis showed that the levels of IL-3Rα and IL-3Rβ expressed on AML cells are heterogeneous and that they clearly correlated with the percentage of apoptotic cells induced by the two IL-3 diphtheria fusion proteins ( Fig. 1 C and D) .
AML cases expressing very low or low levels of IL-3Rα/IL-3Rβ showed only a very low/low rate of cell killing after 24/48h of incubation with the two IL-3 diphtheria fusion proteins (data not shown); AML cases expressing moderate IL-3Rα/IL-3Rβ levels (see 1 representative example in Fig. 2, top For 
